Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aminolevulinic acid - DUSA

Drug Profile

Aminolevulinic acid - DUSA

Alternative Names: 5 ALA; 5-Aminolaevulinic acid; 5-Aminolevulinic acid; ALA - DUSA; aminolevulinic acid HCL - DUSA; Delta-aminolevulinic acid; Levulan PDT; Levulan photodynamic therapy; Levulan/Kerastick; Levulan™

Latest Information Update: 17 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PARTEQ Innovations
  • Developer Cleveland Clinic; DUSA Pharmaceuticals
  • Class Amino acids; Antineoplastics; Keto acids; Levulinic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal dysplasia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • Phase II Basal cell nevus syndrome; Brain cancer; Skin cancer
  • Suspended Warts
  • No development reported Barrett's oesophagus
  • Discontinued Acne vulgaris; Leucoplakia; Oesophageal cancer; Photodamage; Psoriasis

Most Recent Events

  • 26 Dec 2018 DUSA filed a motion for preliminary injunctive relief regarding the patent dispute between DUSA and Biofrontera
  • 24 Jul 2018 DUSA Pharmaceuticals files lawsuit againts Biofrontera for patent infringement, trade secret misappropriation and tortious interferance claims for aminolevulinic acid HCl in the US
  • 03 Nov 2017 DUSA Pharmaceuticals withdraws a phase III trial for Actinic keratosis prior to enrolment in USA due to corporate business decision (Topical) (NCT03024060)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top